Goodfin Deal Room: Inside Dyme — The Insulin Pump Built by Omnipod's Founding Team
The $400B diabetes market has had one patch pump leader for 20 years. Competitors have spent over $1B trying to challenge Omnipod — and failed. Dyme is taking a different approach.
Join us for a Goodfin Deal Room with Chris Hanson, CEO & Co-Founder of Dyme, a stealth-mode medtech company building the world's smallest, most comfortable insulin pump. Chris previously co-founded a VC and NIH-backed diabetes startup and has been investing through Grant Park Ventures for over a decade. His CTO was the co-founder and inventor of Insulet’s (NASDAQ:PODD) Omnipod and other Dyme team members include early Insulet employees.
We'll unpack:
→ Why a $2.6B ARR category leader has zero real competition — and what that means for investors
→ How Dyme built a pump ¼ the size, ½ the height, ⅓ the weight of Omnipod with the same insulin capacity
→ The regulatory path to market — 510(k), no clinical trials, commercial launch by 2028
→ The diabetes exit landscape — $3.7B acquisitions, $20B+ IPOs, and where Dyme fits
→ Their Series A2 raise and how Goodfin members can participate
About the Guest:
Christopher Hanson is the CEO & Co-Founder of Dyme. He previously co-founded Perikinetics, a VC and NIH-backed implantable insulin delivery startup, and spent time at Shifamed (a multi-exit medtech incubator), CoorsTek Medical, and Boston Scientific. He's been investing through Grant Park Ventures for 11 years. Chris holds a Master's from Johns Hopkins in Engineering Management with a Mechanical Engineering focus.
About Goodfin Deal Rooms:
Deal Rooms are intimate sessions where Goodfin members get direct access to founders raising capital. No intermediaries, no polished pitch, a real conversation about the business, the market, and the investment thesis.
This event is exclusive to Goodfin members.
Disclaimer:
The information presented during this event is provided for informational and educational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities or investment products. Nothing discussed should be construed as financial, legal, or tax advice. Any views expressed by speakers are their own and do not necessarily reflect those of the host organization or its affiliates.